Targeting therapy-persistent residual disease

Xiaoxiao Sun,Lani F Wu,Steven J Altschuler,Aaron N Hata

DOI: https://doi.org/10.1038/s43018-024-00819-9

Abstract:Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has emerged as a potential strategy for enhancing the efficacy and the durability of current therapies. However, barriers remain to implementing persister-directed approaches in the clinic. This Perspective discusses current preclinical and clinical complexities and outlines key steps toward the development of clinical strategies that target therapy-persistent residual disease.